Vital Therapies, Inc.

ACTIVE

加利福尼亚州圣迭戈县, California, United Stateswww.vitaltherapies.comPublic51–100 employeesEstablished: 2003-01-01

Part of Immunic

Clinical Trials

7 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2003

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

29.4%

Phase 2

29.4%

Phase 3

17.6%

Trial Status Distribution

Active, not recruiting

41.2%

Completed

23.5%

No Longer Available

5.9%

Terminated

17.6%

Withdrawn

11.8%

Clinical Trials

Trials sponsored by this organization (17)

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

Phase 3

Terminated

interventional

Jan 2016151 participants

This study examines the safety and efficacy of using ELAD treatment as continuous liver support in subjects with liver failure secondary to acute hepatocellular insult with a temporal and causal relationship to alcohol, allowing time for the subject's native liver to recover and be restored to a functional state. The primary objective of the study is to evaluate the safety and efficacy of ELAD with respect to overall survival (OS) of subjects through at least Study Day 91.

Phase 1

Active, not recruiting

Dec 2015150 participants

This study examines the safety and efficacy of using ELAD treatment as continuous liver support in subjects with liver failure secondary to acute hepatocellular insult with a temporal and causal relationship to alcohol, allowing time for the subject's native liver to recover and be restored to a functional state. The primary objective of the study is to evaluate the safety and efficacy of ELAD with respect to overall survival (OS) of subjects through at least Study Day 91.

Phase 1

Active, not recruiting

Dec 2015150 participants

This study examines the safety and efficacy of using ELAD treatment as a continuous liver support to a subject with liver failure secondary to acute hepatocellular insult and alcohol use, allowing time for the subject's native liver to recover and restore to a functional state. The study's primary objective is to evaluate ELAD safety and efficacy on overall survival through at least Study Day 91, with follow-up Protocol VTL-308E providing additional survival data up to a maximum of 5 years.

Phase 1

Active, not recruiting

Nov 2015150 participants

Study examines the safety and efficacy of ELAD treatment as a continuous liver support to a subject with compromised liver function owing to severe acute alcoholic hepatitis who is a Lille score failure (Lille score >0.45), allowing time for the subject's native liver to regenerate to a functional state. The primary objective is to evaluate safety and efficacy with respect to overall survival of subjects through study termination (after last surviving enrolled subject completes Study Day 91).

Active, not recruiting

May 2015150 participants

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

Phase 2

Terminated

interventional

Oct 20148 participants

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Phase 3

Terminated

interventional

Apr 201418 participants

This study examines the safety and efficacy of using ELAD therapy as a continuous liver support in subjects with compromised liver function owing to severe acute alcoholic hepatitis (sAAH), allowing time for the subject's native liver to regenerate to a healthy state. The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival (OS) of subjects through VTI-210 study termination (after the last surviving enrolled subject completes study day 91)

Active, not recruiting

Jul 2013150 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations